TNFRSF17 and Miyoshi myopathy: Indeed, over the last few years, MM has represented one of the cancers that has progressed the most in terms of survival, mainly thanks to the advent of modern monoclonal antibodies (moAbs), such as Daratumumab and Isatuximab, and anti-BCMA, such as Belantamab mafodotin; however, they often do not exceed cytogenetic high risk [102].